Skip to content
10-Q

Quarterly Report

Raphael Pharmaceutical Inc. RAPH

0001213900-26-056181

← back to feed
Filed
May 14, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 14, 2026 20.18M sh
Shares Diluted Q1 2026 · Mar 31, 2026 20.18M sh
Shares Diluted Q1 2026 · Mar 31, 2025 19.63M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$44K
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$209K
Stockholders Equity Q1 2026 · Mar 31, 2026 −$1.66M
Stockholders Equity Q1 2026 · Dec 31, 2025 −$1.43M
Stockholders Equity Q1 2026 · Mar 31, 2025 −$734K
Stockholders Equity Q1 2026 · Dec 31, 2024 −$742K
Current Liabilities Q1 2026 · Mar 31, 2026 $1.67M
Current Liabilities Q1 2026 · Dec 31, 2025 $1.49M
Current Assets Q1 2026 · Mar 31, 2026 $1K
Current Assets Q1 2026 · Dec 31, 2025 $51K
Total Assets Q1 2026 · Mar 31, 2026 $3K
Total Assets Q1 2026 · Dec 31, 2025 $53K
Eps Diluted Q1 2026 · Mar 31, 2026 $0.01
Eps Diluted Q1 2026 · Mar 31, 2025 $0.02
Eps Basic Q1 2026 · Mar 31, 2026 $0.01
Eps Basic Q1 2026 · Mar 31, 2025 $0.02
Sga Expense Q1 2026 · Mar 31, 2026 $186K
Sga Expense Q1 2026 · Mar 31, 2025 $353K
Rd Expense Q1 2026 · Mar 31, 2026 $37K
Rd Expense Q1 2026 · Mar 31, 2025 $72K
Net Income Q1 2026 · Mar 31, 2026 −$229K
Net Income Q1 2026 · Mar 31, 2025 −$429K
Operating Income Q1 2026 · Mar 31, 2026 −$223K
Operating Income Q1 2026 · Mar 31, 2025 −$425K